Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-11-23FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA approved a supplemental application for Humira (adalimumab) filed by Cordavis Limited, indicating regulatory action on a Humira supp…
-
CLINICAL_TRIALS trial_result · 2015-11-05Clinical Trial Update: Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of M518101 in patients with plaque psoriasis has completed.
-
FDA approval · 2015-10-29FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for TACLONEX (calcipotriene and betamethone dipropionate) from LEO Pharma Inc.
-
CLINICAL_TRIALS trial_result · 2015-09-23Clinical Trial Update: Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis [Phase 3]
Phase 3 trial comparing secukinumab to etanercept in moderate to severe chronic plaque psoriasis completed with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-09-02Clinical Trial Update: Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis [Phase 3]
This clinical trial update reports the completion of a Phase 3 study evaluating the efficacy and safety of M518101 in plaque psoriasis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-09-02Clinical Trial Update: Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis [Phase 3]
Phase 3 long-term study evaluating the safety and efficacy of M518101 in subjects with plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2015-08-13Clinical Trial Update: A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis [Phase 3]
Pfizer's Phase 3 long-term study of CP-690,550 (tofacitinib) in adults with moderate-to-severe plaque psoriasis and/or psoriatic arthritis h…
-
CLINICAL_TRIALS research · 2015-07-21Clinical Trial Update: An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
This document describes an observational study evaluating patient-reported experiences of living with moderate-to-severe plaque psoriasis.
-
FDA approval · 2015-07-10FDA Approved: CALCIPOTRIENE — Supplemental Application (Mayne Pharma)
FDA approved a supplemental application for CALCIPOTRIENE submitted by Mayne Pharma.
-
FDA label_change · 2015-06-29FDA Approved: CLOBETASOL PROPIONATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approves a supplemental application for clobetasol propionate from Actavis Pharma, Inc. to update the product labeling.
-
CLINICAL_TRIALS other · 2015-06-24Clinical Trial Update: ASIS for Enbrel in Plaque Psoriasis [Phase 1, Phase 2]
Clinical trial update for ASIS evaluating Enbrel (etanercept) in plaque psoriasis across Phase 1/Phase 2; status is unknown.
-
CLINICAL_TRIALS trial_result · 2015-05-20Clinical Trial Update: Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept [Phase 4]
Phase 4 trial comparing autoinjector preferences in patients with rheumatoid arthritis and plaque psoriasis treated with etanercept; results…
-
CLINICAL_TRIALS trial_result · 2015-05-19Clinical Trial Update: Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens [Phase 3]
Phase 3 trial evaluating different doses and dosing regimens of subcutaneous secukinumab (AIN457) in adults with moderate-to-severe chronic …
-
CLINICAL_TRIALS trial_result · 2015-05-08Clinical Trial Update: Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients [Phase 2]
Phase IIa study evaluating multiple IV doses of AbGn-168H in adults with moderate to severe chronic plaque psoriasis; the study has complete…
-
CLINICAL_TRIALS trial_result · 2015-05-06Clinical Trial Update: A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis [Phase 1]
Phase 1 study evaluating the safety, tolerability, and pharmacodynamics of Dalazatide (ShK-186) over 4 weeks in adults with active plaque ps…
-
CLINICAL_TRIALS withdrawal · 2015-05-06Clinical Trial Update: TSO for Plaque Psoriasis [Phase 2]
A Phase 2 trial evaluating TSO for plaque psoriasis has been withdrawn.
-
FDA label_change · 2015-04-27FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
FDA announces that Amgen's supplemental application for OTEZLA (apremilast) has been approved, updating the product labeling accordingly.
-
CLINICAL_TRIALS withdrawal · 2015-04-21Clinical Trial Update: Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis [Phase 4]
A Phase 4 trial of an injectable biologic with U0279 for severe plaque-type psoriasis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-04-20Clinical Trial Update: NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study [NA]
This clinical trial update presents results from a bilateral pilot study comparing NB-UVB phototherapy with and without a topical LCD treatm…
-
FDA approval · 2015-04-15FDA Approved: DESOXIMETASONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for desoximetasone submitted by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2015-04-13Clinical Trial Update: Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis [Phase 2]
Phase 2 study investigating the mechanism of action of tofacitinib (CP-690,550) in the skin of adults with moderate to severe chronic plaque…
-
FDA approval · 2015-04-13FDA Approved: TRIAMCINOLONE ACETONIDE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved Triamcinolone Acetonide via an Original Application (ANDA) for Padagis Israel Pharmaceuticals Ltd., authorizing a generic corti…
-
CLINICAL_TRIALS trial_result · 2015-04-10Clinical Trial Update: A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis [Phase 1, Phase 2]
This is a completed Phase 1/2 trial comparing AIN457 (secukinumab) to placebo in adults with moderate-to-severe stable plaque psoriasis. Res…
-
CLINICAL_TRIALS trial_result · 2015-03-30Clinical Trial Update: A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003) [Phase 2]
Phase 2 study to determine the optimal dose of tildrakizumab for moderate-to-severe chronic plaque psoriasis completed with posted results i…
-
CLINICAL_TRIALS trial_result · 2015-03-27Clinical Trial Update: AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis [Phase 2]
Phase 2 study of AIN457 (secukinumab) for moderate-to-severe plaque psoriasis completed, with results posted in 2015. Sponsor: Novartis Phar…